Private Equity Track record
  • Xellialogo
    Xellia
    Sweden / Private Equity

    Healthcare

    Overview

    Xellia is a specialty pharmaceutical group focused on the development, manufacturing and global commercialisation of anti-infective therapies. During our ownership, Xellia transformed from a supplier of niche active pharmaceutical ingredients to a fully integrated speciality pharmaceutical company.

    During our investment period, Xellia invested more than $100 million in research and development (‘R&D’) and capacity expansion across its global manufacturing network, including a new fill-finish plant in Copenhagen.

    Highlights

    • Platform created for continued growth and enhanced margins, based on a broadened product range and an exciting pipeline of new products
    • Xellia’s focus on R&D resulted in 15 new product filings in 2012
    • Expanded their global manufacturing network including a new fill-finish plant in Copenhagen
    Key facts
    2.3x Money Multiple on exit
    $100m Invested more than $100 million in R&D
    11% EBITDA growth per annum
    “3i’s investment and continued support, expertise and commitment has enabled Xellia to successfully grow and transition the business to become leaders in the supply of key anti-infective products.” Carl-Åke Carlsson, Chief Executive and President, Xellia

    Regulatory information 
    This transaction involved a recommendation of 3i Investments plc, advised by 3i Sweden.

Back to top